MTOR kinase inhibitors promote antibody class switching via mTORC2 inhibition

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 47, 2014, Pages E5076-E5085

  Limon, Jose J ^a,b   So, Lomon ^a,b   Jellbauer, Stefan ^b   Chiu, Honyin ^a,b   Corado, Juana ^a   Sykes, Stephen M ^c   Raffatellu, Manuela ^b   Fruman, David A ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c FOX CHASE CANCER CENTER   (United States)

Author keywords

Blymphocyte; Class switching; Differentiation; Kinase; Rapamycin

Indexed keywords

AZD 8055; IMMUNOGLOBULIN M; IMMUNOSUPPRESSIVE AGENT; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; OVALBUMIN; RAPAMYCIN; RNA; IMMUNOGLOBULIN G; MULTIPROTEIN COMPLEX; PROTEIN KINASE INHIBITOR; TARGET OF RAPAMYCIN KINASE; TOR COMPLEX 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; B CELL CULTURE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; BACTERIAL GROWTH; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; IMMUNIZATION; LOW DRUG DOSE; MOUSE; NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; SALMONELLA TYPHIMURIUM; SPLEEN CELL; ALLOSTERISM; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; C57BL MOUSE; DRUG EFFECTS; GENE REARRANGEMENT;

MAMMALIA; MUS;

ALLOSTERIC REGULATION; ANIMALS; IMMUNOGLOBULIN CLASS SWITCHING; IMMUNOGLOBULIN G; MICE; MICE, INBRED C57BL; MULTIPROTEIN COMPLEXES; PROTEIN KINASE INHIBITORS; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84913594343     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1407104111     Document Type: Article

References (36)

1. Limon JJ, Fruman DA (2012) Akt and mTOR in B Cell Activation and Differentiation. Front Immunol 3:228
2. Powell JD, Pollizzi KN, Heikamp EB, Horton MR (2012) Regulation of immune responses by mTOR. Annu Rev Immunol 30:39-68
3. Laplante M, Sabatini DM (2012) mTOR signaling in growth control and disease. Cell 149(2):274-293
4. Guertin DA, et al. (2006) Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev Cell 11(6):859-871
5. Jacinto E, et al. (2006) SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 127(1):125-137
6. Zhang S, et al. (2013) B cell-specific deficiencies in mTOR limit humoral immune responses. J Immunol 191(4):1692-1703
7. Lee K, et al. (2013) Requirement for Rictor in homeostasis and function of mature B lymphoid cells. Blood 122(14):2369-2379
8. Aagaard-Tillery KM, Jelinek DF (1994) Inhibition of human B lymphocyte cell cycle progression and differentiation by rapamycin. Cell Immunol 156(2):493-507
9. Janes MR, et al. (2010) Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat Med 16(2):205-213
10. Keating R, et al. (2013) The kinase mTOR modulates the antibody response to provide cross-protective immunity to lethal infection with influenza virus. Nat Immunol 14(12):1266-1276
11. Janes MR, Fruman DA (2010) Targeting TOR dependence in cancer. Oncotarget 1(1): 69-76
12. Wander SA, Hennessy BT, Slingerland JM (2011) Next-generation mTOR inhibitors in clinical oncology: How pathway complexity informs therapeutic strategy. J Clin Invest 121(4):1231-1241
13. Xu Z, Zan H, Pone EJ, Mai T, Casali P (2012) Immunoglobulin class-switch DNA recombination: Induction, targeting and beyond. Nat Rev Immunol 12(7):517-531
14. Zhang TT, Makondo KJ, Marshall AJ (2012) p110d phosphoinositide 3-kinase represses IgE switch by potentiating BCL6 expression. J Immunol 188(8):3700-3708
15. Zhang TT, et al. (2008) Genetic or pharmaceutical blockade of p110delta phosphoinositide 3-kinase enhances IgE production. J Allergy Clin Immunol 122:811-819 e812
16. Chresta CM, et al. (2010) AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res 70(1):288-298
17. Willems L, et al. (2012) The dual mTORC1 and mTORC2 inhibitor AZD8055 has antitumor activity in acute myeloid leukemia. Leukemia 26(6):1195-1202
18. Rolf J, et al. (2010) Phosphoinositide 3-kinase activity in T cells regulates the magnitude of the germinal center reaction. J Immunol 185(7):4042-4052
19. Cunningham AF, et al. (2007) Salmonella induces a switched antibody response without germinal centers that impedes the extracellular spread of infection. J Immunol 178(10):6200-6207
20. Matsiota-Bernard P, Mahana W, Avrameas S, Nauciel C (1993) Specific and natural antibody production during Salmonella typhimurium infection in genetically susceptible and resistant mice. Immunology 79(3):375-380
21. Haynes L, Eaton SM, Burns EM, Randall TD, Swain SL (2003) CD4 T cell memory derived from young naive cells functions well into old age, but memory generated from aged naive cells functions poorly. Proc Natl Acad Sci USA 100(25):15053-15058
22. Dengler HS, et al. (2008) Distinct functions for the transcription factor Foxo1 at various stages of B cell differentiation. Nat Immunol 9(12):1388-1398
23. Sykes SM, et al. (2011) AKT/FOXO signaling enforces reversible differentiation blockade in myeloid leukemias. Cell 146(5):697-708
24. Tothova Z, et al. (2007) FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. Cell 128(2):325-339
25. Omori SA, et al. (2006) Regulation of class-switch recombination and plasma cell differentiation by phosphatidylinositol 3-kinase signaling. Immunity 25(4):545-557
26. Jiang Q, et al. (2011) mTOR kinase inhibitor AZD8055 enhances the immunotherapeutic activity of an agonist CD40 antibody in cancer treatment. Cancer Res 71(12): 4074-4084
27. Amiel E, et al. (2012) Inhibition of mechanistic target of rapamycin promotes dendritic cell activation and enhances therapeutic autologous vaccination in mice. J Immunol 189(5):2151-2158
28. Janes MR, Fruman DA (2009) Immune regulation by rapamycin: moving beyond T cells. Sci Signal 2(67):pe25
29. Sengupta S, Peterson TR, Laplante M, Oh S, Sabatini DM (2010) mTORC1 controls fasting-induced ketogenesis and its modulation by ageing. Nature 468(7327): 1100-1104
30. Shiota C, Woo JT, Lindner J, Shelton KD, Magnuson MA (2006) Multiallelic disruption of the rictor gene in mice reveals that mTOR complex 2 is essential for fetal growth and viability. Dev Cell 11(4):583-589
31. Houghton PJ, et al. (2012) Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program. Pediatr Blood Cancer 58(2): 191-199
32. Donahue AC, Fruman DA (2003) Proliferation and survival of activated B cells requires sustained antigen receptor engagement and phosphoinositide 3-kinase activation. J Immunol 170(12):5851-5860
33. Rüssmann H, et al. (1998) Delivery of epitopes by the Salmonella type III secretion system for vaccine development. Science 281(5376):565-568
34. Kaniga K, Uralil J, Bliska JB, Galán JE (1996) A secreted protein tyrosine phosphatase with modular effector domains in the bacterial pathogen Salmonella typhimurium. Mol Microbiol 21(3):633-641
35. Hoiseth SK, Stocker BA (1981) Aromatic-dependent Salmonella typhimurium are nonvirulent and effective as live vaccines. Nature 291(5812):238-239
36. Donahue AC, Fruman DA (2007) Distinct signaling mechanisms activate the target of rapamycin in response to different B-cell stimuli. Eur J Immunol 37(10):2923-2936